All In Biotech

BLA 021081 · Sanofi Aventis US

Lantus Solostar

Insulin Glargine Recombinant · Injection · Insulin Analog

Novel

Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Apr 20, 2000

Approved uses

5

Original approval plus efficacy supplements

Registered trials

9

3 Phase 3, 0 recruiting

FAERS reports

202,872

112,860 serious, 12,531 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2025.

LANTUS is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. LANTUS is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 ) Limitations of Use Not recommended for the treatment of diabetic ketoacidosis. ( 1 ) Limitations of Use LANTUS is not recommended for the treatment of diabetic ketoacidosis.

Mechanism: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • LANTUS SOLOSTAR · INSULIN GLARGINE RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, INJECTION · Prescription
  • LANTUS · INSULIN GLARGINE RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Glargine Recombinant" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased29,554
  • off label use13,004
  • nausea8,711
  • drug ineffective8,451
  • inappropriate schedule of product administration8,366
  • blood glucose decreased8,334
  • hypoglycaemia7,179
  • product storage error6,908
  • visual impairment6,568
  • diarrhoea6,177
  • fatigue6,032
  • dyspnoea5,652

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,035
20051,804
20063,270
20073,327
20082,949
20093,916
20105,398
20116,269
20125,590
20138,148
201412,103
201518,871
201612,475
201711,285
201816,789
201913,842
202011,767
202110,694
20229,994
20238,875
202410,646
202513,310
202610,512

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lantus (Insulin Glargine,Hum.Rec.Anlog)

2024 spending

$140M

Beneficiaries

271,761

1,116,800 claims

Per beneficiary

$515

$6.25 per unit

View as table
YearSpending
2020$1,055,722,607
2021$958,653,939
2022$833,484,770
2023$735,735,411
2024$139,894,057

Part D: Lantus Solostar (Insulin Glargine,Hum.Rec.Anlog)

2024 spending

$699M

Beneficiaries

1,415,422

5,570,732 claims

Per beneficiary

$494

$6.11 per unit

View as table
YearSpending
2020$2,663,360,232
2021$2,831,447,261
2022$2,873,658,630
2023$3,157,233,282
2024$699,132,486

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Sanofi · Also marketed as Lantus

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.